0 Évaluations
ID

28335

Description

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Mots-clés

Versions (2)
  1. 30/11/2017 30/11/2017 -
  2. 04/01/2018 04/01/2018 -
Détendeur de droits

Prof. Dr. med. Georg Heß

Téléchargé le

4 janvier 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

  • Plus récent
  • Plus ancien
  • Favori
  • Plus récent
    • Plus récent
    • Plus ancien
    • Favori

    Aucun commentaire

    Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

    Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003

    Anglais

    Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003

    1 Formulaires  
    Admininstrative data
    Description

    Admininstrative data

    Alias
    UMLS CUI-1
    C1320722
    Subject ID
    Description

    Subject ID

    Type de données

    text

    Alias
    UMLS CUI [1]
    C2348585
    Exclusion criteria
    Description

    Exclusion criteria

    Alias
    UMLS CUI-1
    C0680251
    1. Lymphoma other than DLBCL, FL IIIB, transfomed indolent NHL
    Description

    Lymphoma other

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0024299
    UMLS CUI [1,2]
    C0205394
    2. CNS involvement (brain MRI is required only in cases of clinically suspicious involvement)
    Description

    CNS involvement

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0449389
    3. Pregnant or breastfeeding women
    Description

    Pregnancy

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0032961
    4. Severe concomitant disease
    Description

    e.g. uncontrolled arterial hypertension, heart failure (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled hyperlipoproteinaemia

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0243087
    UMLS CUI [1,2]
    C0205082
    5. Myocardial infarction within the last 6 months
    Description

    Myocardial infarction

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0027051
    6. Active uncontrolled infections incl. HIV-positivity, active Hepatitis B or C
    Description

    Hepatitis B Hepatitis C HIV-positive

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0019163
    UMLS CUI [1,2]
    C0019196
    UMLS CUI [1,3]
    C0019682
    7. Vaccination with live vaccine within last 4 weeks
    Description

    Vaccination

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0042196
    8. Mental status precluding patient's compliance
    Description

    Mental status compliance

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0278060
    UMLS CUI [1,2]
    C1321605
    9. Known CD20 negativity
    Description

    CD20 negativity

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0054946
    UMLS CUI [1,2]
    C0205160
    10. Diagnosed or treated for a malignancy other than NHL
    Description

    Except: adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the Cervix, DCIS of the breast, or other solid tumors curatively treated with no evidence of disease for >3 years, or prostate cancer with a life expectancy of more than 2 years

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0009488
    UMLS CUI [1,2]
    C0006826
    11. Treatment with any approved anticancer agent within last 2 weeks
    Description

    Any agents must have been stoppped at least 2 weeks prior to day 1 of GOAL treatment and all treatment-related adverse events must have returned to Grade 1.

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0920425
    UMLS CUI [1,2]
    C0003392
    12. Prior exposition to Obinutuzumab or Pixantrone
    Description

    therapy Obinutuzumab Pixantrone

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0087111
    UMLS CUI [1,2]
    C2742503
    UMLS CUI [1,3]
    C0253355
    13. History of hypersensitivity to medicinal products with similar chemical structure as the trial medication
    Description

    Hypersensitivity Investigational New Drugs

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0020517
    UMLS CUI [1,2]
    C0013230
    14. Active participation in other interventional clinical trials during the present clinical trial or within the last 2 weeks prior to treatment initiation
    Description

    Concurrent participation in non-treatment studies is not excluded.

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C2348568
    15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.
    Description

    Compliance behavior Limited (extensiveness) Comorbidity

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C1321605
    UMLS CUI [1,2]
    C0439801
    UMLS CUI [1,3]
    C0009488
    Retour au début de la page

    Similar models

    Screening Exclusion criteria GOAL Trial B-cell Lymphoma NCT02499003

    1 Formulaires
    Name
    Type
    Description | Question | Decode (Coded Value)
    Type de données
    Alias
    Item Group
    Admininstrative data
    C1320722 (UMLS CUI-1)
    Subject ID
    Item
    Subject ID
    text
    C2348585 (UMLS CUI [1])
    Item Group
    Exclusion criteria
    C0680251 (UMLS CUI-1)
    Lymphoma other
    Item
    1. Lymphoma other than DLBCL, FL IIIB, transfomed indolent NHL
    boolean
    C0024299 (UMLS CUI [1,1])
    C0205394 (UMLS CUI [1,2])
    CNS involvement
    Item
    2. CNS involvement (brain MRI is required only in cases of clinically suspicious involvement)
    boolean
    C0449389 (UMLS CUI [1])
    Pregnancy
    Item
    3. Pregnant or breastfeeding women
    boolean
    C0032961 (UMLS CUI [1])
    Severe concomitant disease
    Item
    4. Severe concomitant disease
    boolean
    C0243087 (UMLS CUI [1,1])
    C0205082 (UMLS CUI [1,2])
    Myocardial infarction
    Item
    5. Myocardial infarction within the last 6 months
    boolean
    C0027051 (UMLS CUI [1])
    Hepatitis B Hepatitis C HIV-positive
    Item
    6. Active uncontrolled infections incl. HIV-positivity, active Hepatitis B or C
    boolean
    C0019163 (UMLS CUI [1,1])
    C0019196 (UMLS CUI [1,2])
    C0019682 (UMLS CUI [1,3])
    Vaccination
    Item
    7. Vaccination with live vaccine within last 4 weeks
    boolean
    C0042196 (UMLS CUI [1])
    Mental status compliance
    Item
    8. Mental status precluding patient's compliance
    boolean
    C0278060 (UMLS CUI [1,1])
    C1321605 (UMLS CUI [1,2])
    CD20 negativity
    Item
    9. Known CD20 negativity
    boolean
    C0054946 (UMLS CUI [1,1])
    C0205160 (UMLS CUI [1,2])
    comorbidity Malignant Neoplasms
    Item
    10. Diagnosed or treated for a malignancy other than NHL
    boolean
    C0009488 (UMLS CUI [1,1])
    C0006826 (UMLS CUI [1,2])
    Treatment anticancer agent
    Item
    11. Treatment with any approved anticancer agent within last 2 weeks
    boolean
    C0920425 (UMLS CUI [1,1])
    C0003392 (UMLS CUI [1,2])
    therapy Obinutuzumab Pixantrone
    Item
    12. Prior exposition to Obinutuzumab or Pixantrone
    boolean
    C0087111 (UMLS CUI [1,1])
    C2742503 (UMLS CUI [1,2])
    C0253355 (UMLS CUI [1,3])
    Hypersensitivity Investigational New Drugs
    Item
    13. History of hypersensitivity to medicinal products with similar chemical structure as the trial medication
    boolean
    C0020517 (UMLS CUI [1,1])
    C0013230 (UMLS CUI [1,2])
    study subject participation status
    Item
    14. Active participation in other interventional clinical trials during the present clinical trial or within the last 2 weeks prior to treatment initiation
    boolean
    C2348568 (UMLS CUI [1])
    Compliance behavior Limited (extensiveness) Comorbidity
    Item
    15. Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial.
    boolean
    C1321605 (UMLS CUI [1,1])
    C0439801 (UMLS CUI [1,2])
    C0009488 (UMLS CUI [1,3])
    Retour au début de la page 

    Aide

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial